companydata.dkNovo Nordisk Invest 4 A/S: Financial statements 2017
CVR: 31853923
Novo Nordisk Invest 4 A/S (CVR 31853923) has filed annual accounts for 2017. In 2017, the company reported a net result of DKK -775,000 compared with DKK -407,000 the year before. Equity amounted to DKK 9,120,000. The solvency ratio was 78.9%.
- Profit/Loss
- -775,000 kr.
- Equity
- 9,120,000 kr.
- Total Assets
- 11,554,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | - | - | -775 t. | 9.1 mio. | - |
| 2016 | - | - | -407 t. | 9.9 mio. | - |
| 2015 | 219.3 mio. | - | 803 t. | 10.3 mio. | - |
| 2013 | 181.8 mio. | - | -214 t. | 5.7 mio. | - |
Find more companies like Novo Nordisk Invest 4 A/S
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2017
As of June 1, 2017, Lene Moth Bang has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of June 1, 2017, Lars Fruergaard Jørgensen has left the board of directors of Novo Nordisk Invest 4 A/S.
Novo Nordisk Invest 4 A/S has published its annual report for 2016. The net result was DKK -407,000.
As of January 1, 2017, Ole Falvig Ramsby has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Jesper Brandgaard has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Lars Fruergaard Jørgensen has joined the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Anne Birgitte Urup Hemmingsen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Birgitte Nauntofte has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Kirsten Engelhard Nielsen has left the board of directors of Novo Nordisk Invest 4 A/S.
As of January 1, 2017, Mads Krogsgaard Thomsen has left the board of directors of Novo Nordisk Invest 4 A/S.
About Novo Nordisk Invest 4 A/S
Novo Nordisk Invest 4 A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2008. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named STENO DIABETES CENTER A/S. The management consists of Anders Rytter Mikkelsen. The company is owned by NOVO NORDISK A/S. The company has 0 employees. In 2025, the company reported a gross profit of DKK -64,000 and a net result of DKK -23,000 compared with DKK 7,000 the year before. Equity amounted to DKK 1,772,000.